Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Current and Future Treatments for Diabetic Retinopathy"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (1 June 2021) | Viewed by 16060
Special Issue Editors
2. Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, From Physiopathology of Ocular Diseases to Clinical Development, 75006 Paris, France
3. Cochin Hospital, AP-HP, Assistance Publique Hôpitaux de Paris, 24 rue du Faubourg Saint Jacques, 75014 Paris, France
Interests: neuroprotection; diabetic retinopathy; retinal ischemia; glia; drug development
Special Issues, Collections and Topics in MDPI journals
Interests: retina; retinal imaging; diabetic retinopathy; surgical retina; cell therapy
Special Issue Information
Diabetic retinopathy remains the first cause of blindness in the younger and active population, despite the major recent advances achieved in the reduction of diabetic macular edema (DME). In fact, many aspects of diabetic retinopathy are not targeted by anti-VEGF therapy or by corticosteroids, and vision gain still remains limited for many patients.
New molecular targets have been identified in diabetic retinopathy pathogenesis, which are involved in ischemia, neuronal cell death, glial metabolism, or vasculopathy, and old drugs as well as new drug candidates targeting these pathways have been discovered and evaluated in animal models.
In this Special Issue, we will summarize the benefits of the treatments currently available for DME and present potential new drug candidates for this devastating disease.
Prof. Francine Behar-Cohen
Prof. Dr. Anat Lowenstein
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- diabetic retinopathy
- retinal ischemia
- drug targeting
- drug development